The most common linifanib-related AEs in the present study (hypertension, rash, neutropenia, proteinuria, weight decreased, leukopenia, fatigue, palmar-plantar erythrodysaesthesia) as well as linifanib-related Grade 3 AEs (proteinuria, diarrhea, neutropenia, increased ALT, and increased blood magnesium) were comparable to the most common drug-related AEs in other phase 1, dose-escalating studies in multi-targeted TKIs [14, 21–32]. Here, GPT is linked to neutropenia.